Clinical Trials
As an infrastructure at the German Center for Infection Research (DZIF), the Clinical Trial Unit tracks DZIF's study activities in the “Healex Site Management System (SMS)”. Studies are sorted by indication and are continuously updated.
The study register has recently been expanded to include the category “COVID-19”. For the first time, not only DZIF study activities are presented here: In order to provide a comprehensive overview in the current pandemic situation of planned and already active COVID-19 studies in Germany, the Clinical Trial Unit is cooperating with researchers from various German Centers for Health Research and other networks.
For researchers: If your study is not yet included in our portal, please contact the project management of the Clinical Trial Unit.
COVID-19 Clinical Trials Master Protocol
- Overall study
- Study Sites (1)
Acronym | ISRCTN | EudraCT | NCT (clinicaltrials.gov) | DRKS |
---|---|---|---|---|
A Multi-center, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients
Status: Active
Purpose / Objectives
Primary Outcome
Protocol according to the master protocol “A Multi-center, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients”
Based on the recently published WHO master protocol, the BIH Clinical Study Center (BIH CSC) has developed a central COVID-19 master protocol to harmonize and speed up initiation of COVID-19 clinical trials. The master protocol is available from CSC or via covid19-researchboard@charite.de .
Diagnosis
- COVID-19 infection
Depending individual clinical trial
Target population
Inclusion criteria
Depending on individual clinical trial
Exclusion criteria
Depending on individual clinical trial
Documents (password protected)
Go to download area (no documents yet)